Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2025)

Xeris Biopharma Holdings' Accumulated Expenses history spans 6 years, with the latest figure at $33.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 19.62% year-over-year to $33.2 million, compared with a TTM value of $33.2 million through Dec 2025, up 19.62%, and an annual FY2025 reading of $33.2 million, up 19.62% over the prior year.
  • Accumulated Expenses for Q4 2025 was $33.2 million at Xeris Biopharma Holdings, up from $30.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $49.1 million in Q4 2021, with the low at $19.1 million in Q3 2023.
  • Average Accumulated Expenses over 5 years is $28.1 million, with a median of $24.3 million recorded in 2024.
  • Year-over-year, Accumulated Expenses surged 208.83% in 2021 and then crashed 49.42% in 2023.
  • Tracing XERS's Accumulated Expenses over 5 years: stood at $49.1 million in 2021, then decreased by 25.06% to $36.8 million in 2022, then crashed by 36.09% to $23.5 million in 2023, then increased by 17.89% to $27.7 million in 2024, then grew by 19.62% to $33.2 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Accumulated Expenses are $33.2 million (Q4 2025), $30.4 million (Q3 2025), and $25.0 million (Q2 2025).